Ozoralizumab: Difference between revisions
Content deleted Content added
Script assisted update of identifiers for the Chem/Drugbox validation project (updated: 'CAS_number'). |
m Moving Category:Pfizer brands to Category:Drugs developed by Pfizer per Wikipedia:Categories for discussion/Log/2023 December 9#Category:AstraZeneca brands |
||
| (18 intermediate revisions by 16 users not shown) | |||
| Line 1: | Line 1: | ||
{{Short description|Monoclonal antibody}} |
|||
{{Drugbox |
{{Drugbox |
||
| Verifiedfields = changed |
|||
| Watchedfields = changed |
|||
| verifiedrevid = 458269333 |
|||
| type = mab |
| type = mab |
||
| image = |
| image = |
||
| Line 5: | Line 9: | ||
| mab_type = mab |
| mab_type = mab |
||
| source = zu |
| source = zu |
||
| target = |
| target = |
||
| tradename = |
| tradename = |
||
| Drugs.com = |
| Drugs.com = |
||
| MedlinePlus = |
| MedlinePlus = |
||
| Line 12: | Line 16: | ||
| pregnancy_US = <!-- A / B / C / D / X --> |
| pregnancy_US = <!-- A / B / C / D / X --> |
||
| pregnancy_category= |
| pregnancy_category= |
||
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled--> |
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled--> |
||
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII --> |
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII --> |
||
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM --> |
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM --> |
||
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> |
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> |
||
| legal_status = |
| legal_status = |
||
| routes_of_administration = |
| routes_of_administration = |
||
| bioavailability = |
| bioavailability = |
||
| Line 23: | Line 27: | ||
| elimination_half-life = |
| elimination_half-life = |
||
| excretion = |
| excretion = |
||
| CAS_number |
| CAS_number 1167985-17-2 |
||
| CAS_number_Ref = {{cascite|correct|CAS}} |
|||
| UNII_Ref = {{fdacite|correct|FDA}} |
|||
| UNII = 05ZCK72TXZ |
|||
| ATC_prefix = none |
| ATC_prefix = none |
||
| ATC_suffix = |
| ATC_suffix = |
||
| PubChem = |
| PubChem = |
||
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
|||
| DrugBank = |
| DrugBank = |
||
| |
| = |
||
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} |
|||
| ⚫ | |||
| ChemSpiderID = none |
|||
| molecular_weight = 38.43 kDa |
|||
| ⚫ | |||
}} |
}} |
||
'''Ozoralizumab''' (trade name '''Nanozora''') is a trivalent anti-tumour necrosis factor alpha (TNFα) nanobody designed for the treatment of inflammatory diseases.<ref>{{cite journal |vauthors=Kratz F, Elsadek B |title=Clinical impact of serum proteins on drug delivery |journal=J Control Release |volume=161 |issue=2 |pages=429–45 |date=July 2012 |pmid=22155554 |doi=10.1016/j.jconrel.2011.11.028 }}</ref> |
|||
'''Ozoralizumab''' is a humanized monoclonal antibody designed for the treatment of inflammatory diseases. |
|||
Ozoralizumab was developed by [[Pfizer]] Inc, and now belongs to [[Ablynx]] NV. Ablynx has licensed the rights to the antibody in China to [[Eddingpharm]]. In 2022, ozoralizumab was approved in Japan for the treatment of [[rheumatoid arthritis]].<ref>{{cite press release | url = https://www.taisho.co.jp/global/news/2022/20220926001109.html | title = Notification of Approval to Manufacture and Market Nanozora® 30mg Syringes for S.C. Injection, a Therapy for Rheumatoid Arthritis, in Japan Japan's First NANOBODY® Therapeutic | date = September 26, 2022 | publisher = Taisho Pharmaceutical Holdings }}</ref> |
|||
| ⚫ | |||
== References == |
== References == |
||
<references/> |
<references/> |
||
{{monoclonals for immune system}} |
{{monoclonals for immune system}} |
||
[[Category:Pfizer]] |
|||
| ⚫ | |||
{{monoclonal-antibody-stub}} |
{{monoclonal-antibody-stub}} |
||